Literature DB >> 19885347

How much do forgotten insulin injections matter to hemoglobin a1c in people with diabetes? A simulation study.

Jette Randløv1, Jens Ulrik Poulsen.   

Abstract

BACKGROUND: Forgotten or omitted insulin injections are an important contributing factor to poor glycemic control in people with type 1 diabetes. This study uses mathematical modeling and examines the impact on hemoglobin A1c (HbA1c) levels if insulin injections are forgotten. The simulation concerns people with type 1 diabetes on intensive insulin therapy.
METHODS: Five sets of blood glucose profiles with and without a forgotten injection were obtained. The difference to HbA1c was calculated using an HbA1c estimator on the profiles and was multiplied by the frequency of forgotten events. A frequency of 2.1 forgotten injections per week was found in the literature.
RESULTS: Calculations showed that forgetting 2.1 meal-related injections per week would lead to an increase in HbA1c of at least 0.3-0.4% points, and similarly 0.2-0.3% points related to forgotten injections of the long-acting insulin. In case of even more pronounced nonadherence (e.g., if 39% of all injections are forgotten) there is a possible increase of HbA1c of 1.8% points.
CONCLUSIONS: The magnitude of the possible improvement in HbA1c agrees well with other studies in the relation between adherence and HbA1c levels. The estimated numbers suggest that missing injections are an important reason for suboptimal treatment.

Entities:  

Keywords:  HbA1c; adherence; compliance; self-treatment

Year:  2008        PMID: 19885347      PMCID: PMC2771482          DOI: 10.1177/193229680800200209

Source DB:  PubMed          Journal:  J Diabetes Sci Technol        ISSN: 1932-2968


  13 in total

1.  Standards of medical care in diabetes--2007.

Authors: 
Journal:  Diabetes Care       Date:  2007-01       Impact factor: 19.112

2.  Variability in the relationship between mean plasma glucose and HbA1c: implications for the assessment of glycemic control.

Authors:  Eric S Kilpatrick; Alan S Rigby; Stephen L Atkin
Journal:  Clin Chem       Date:  2007-03-23       Impact factor: 8.327

3.  The influence of insulin use on glycemic control: How well do adults follow prescriptions for insulin?

Authors:  Joyce A Cramer; Mary Jo Pugh
Journal:  Diabetes Care       Date:  2005-01       Impact factor: 19.112

4.  Defining the relationship between plasma glucose and HbA(1c): analysis of glucose profiles and HbA(1c) in the Diabetes Control and Complications Trial.

Authors:  Curt L Rohlfing; Hsiao-Mei Wiedmeyer; Randie R Little; Jack D England; Alethea Tennill; David E Goldstein
Journal:  Diabetes Care       Date:  2002-02       Impact factor: 19.112

Review 5.  Compartmental models for glycaemic prediction and decision-support in clinical diabetes care: promise and reality.

Authors:  E D Lehmann; T Deutsch
Journal:  Comput Methods Programs Biomed       Date:  1998-05       Impact factor: 5.428

6.  Adherence to insulin treatment, glycaemic control, and ketoacidosis in insulin-dependent diabetes mellitus. The DARTS/MEMO Collaboration. Diabetes Audit and Research in Tayside Scotland. Medicines Monitoring Unit.

Authors:  A D Morris; D I Boyle; A D McMahon; S A Greene; T M MacDonald; R W Newton
Journal:  Lancet       Date:  1997-11-22       Impact factor: 79.321

7.  Medication adherence and the associated health-economic impact among patients with type 2 diabetes mellitus converting to insulin pen therapy: an analysis of third-party managed care claims data.

Authors:  Won Chan Lee; Sanjeev Balu; David Cobden; Ashish V Joshi; Chris L Pashos
Journal:  Clin Ther       Date:  2006-10       Impact factor: 3.393

8.  What is the relative contribution of blood glucose levels at different time points of the day to HbA1c in Type 1 diabetes?

Authors:  N Hillman; L Herranz; C Grande; P M Vaquero; L F Pallardo
Journal:  Diabet Med       Date:  2004-05       Impact factor: 4.359

9.  The effect of intensive treatment of diabetes on the development and progression of long-term complications in insulin-dependent diabetes mellitus.

Authors:  D M Nathan; S Genuth; J Lachin; P Cleary; O Crofford; M Davis; L Rand; C Siebert
Journal:  N Engl J Med       Date:  1993-09-30       Impact factor: 91.245

10.  The glucose area under the profiles obtained with continuous glucose monitoring system relationships with HbA(lc) in pediatric type 1 diabetic patients.

Authors:  Silvana Salardi; Stefano Zucchini; Roberta Santoni; Luca Ragni; Stefano Gualandi; Alessandro Cicognani; Emanuele Cacciari
Journal:  Diabetes Care       Date:  2002-10       Impact factor: 19.112

View more
  17 in total

1.  A 16-week open-label, multicenter pilot study assessing insulin pump therapy in patients with type 2 diabetes suboptimally controlled with multiple daily injections.

Authors:  Juan P Frias; Bruce W Bode; Timothy S Bailey; Mark S Kipnes; Rocco Brunelle; Steven V Edelman
Journal:  J Diabetes Sci Technol       Date:  2011-07-01

2.  Pharmacoadherence: An Opportunity for Digital Health to Inform the Third Dimension of Pharmacotherapy for Diabetes.

Authors:  David C Klonoff; Jennifer Y Zhang; Trisha Shang; Chhavi Mehta; David Kerr
Journal:  J Diabetes Sci Technol       Date:  2020-12-08

3.  Efficacy and safety of ultra-long-acting insulin degludec.

Authors:  Ammar Wakil; Stephen L Atkin
Journal:  Ther Adv Endocrinol Metab       Date:  2012-04       Impact factor: 3.565

4.  No effect of insulin pen with memory function on glycemic control in a patient cohort with poorly controlled type 1 diabetes: a randomized open-label study.

Authors:  Thomas Danne; Thomas Forst; Jürgen Deinhard; Ludger Rose; Elisabeth Moennig; Axel Haupt
Journal:  J Diabetes Sci Technol       Date:  2012-11-01

5.  An analysis of "no effect of insulin pen with memory function on glycemic control in a patient cohort with poorly controlled type 1 diabetes: a randomized open-label study".

Authors:  Francisco Javier Ampudia-Blasco
Journal:  J Diabetes Sci Technol       Date:  2012-11-01

6.  Building a Data-Driven Multiple Daily Insulin Therapy Model Using Smart Insulin Pens.

Authors:  Rocio Harbison; Michele Hecht; Janice MacLeod
Journal:  J Diabetes Sci Technol       Date:  2020-08-24

7.  Smart Insulin Pens: Advancing Digital Transformation and a Connected Diabetes Care Ecosystem.

Authors:  Tejaswi Kompala; Aaron B Neinstein
Journal:  J Diabetes Sci Technol       Date:  2021-01-12

8.  Efficacy and safety of insulin degludec in a flexible dosing regimen vs insulin glargine in patients with type 1 diabetes (BEGIN: Flex T1): a 26-week randomized, treat-to-target trial with a 26-week extension.

Authors:  Chantal Mathieu; Priscilla Hollander; Bresta Miranda-Palma; John Cooper; Edward Franek; David Russell-Jones; Jens Larsen; Søren Can Tamer; Stephen C Bain
Journal:  J Clin Endocrinol Metab       Date:  2013-02-07       Impact factor: 5.958

9.  Evaluation of preference for a novel durable insulin pen with memory function among patients with diabetes and health care professionals.

Authors:  Gerhard Klausmann; Irene Hramiak; Marianne Qvist; Kristian Handberg Mikkelsen; Xiaohui Guo
Journal:  Patient Prefer Adherence       Date:  2013-04-05       Impact factor: 2.711

10.  The efficacy and safety of insulin degludec given in variable once-daily dosing intervals compared with insulin glargine and insulin degludec dosed at the same time daily: a 26-week, randomized, open-label, parallel-group, treat-to-target trial in individuals with type 2 diabetes.

Authors:  Luigi Meneghini; Stephen L Atkin; Stephen C L Gough; Itamar Raz; Lawrence Blonde; Marina Shestakova; Stephen Bain; Thue Johansen; Kamilla Begtrup; Kåre I Birkeland
Journal:  Diabetes Care       Date:  2013-01-22       Impact factor: 19.112

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.